Published
September 13, 2024
L’Oréal is once again strengthening its expertise in biotechnologies. Alongside German speciality chemical ingredients manufacturer Evonik, the global beauty giant has taken a minority stake in Abolis Biotechnologies, a company based in Evry (Essonne), near Paris, specialising in the manufacture of ingredients derived from micro-organisms for the cosmetics, pharmaceutical and food markets.
The investment companies Deep Tech & Climate Fund, Clay Partners, Icos Capital and Liberset are also taking part in this €35 million fund-raising.
This equity investment, which is being made via BOLD, L’Oréal’s private equity fund, is also accompanied by an industrial partnership aimed at producing “specific, sustainable ingredients in the quantities needed to meet global demand for responsible beauty,” says the L’Oréal group, which has started working with Abolis from 2019.
According to Reuters, since its creation in 2014 Abolis had only raised €1.1 million.
In 2023, L’Oréal, which has 20 research centres in 11 countries, had sales of €41 billion.
Copyright © 2024 FashionNetwork.com All rights reserved.
Published September 19, 2024 Science and fashion are not natural allies. The rigor of the first often clashing with the fantasy of the latter, but
Published September 19, 2024 Footasylum is to upsize its flagship store at the Merry Hill mall with the shoe and streetwear retailer set to triple
Published September 19, 2024 Long-standing Covert Garden retail resident Oakley has reimagined its sports eyewear store, and is set to reopen the L
Published September 19, 2024 Digital retailer Very Group has “reimagined” its retail media proposition with the launch of Very Media Group (VMG